Recruitment

Recruitment Status
Active, not recruiting
Estimated Enrollment
37

Summary

Conditions
  • Nodal Marginal Zone B-cell Lymphoma
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • Recurrent Grade 1 Follicular Lymphoma
  • Recurrent Mantle Cell Lymphoma
  • Recurrent Small Lymphocytic Lymphoma
  • Recurrent Grade 2 Follicular Lymphoma
  • Anaplastic Large Cell Lymphoma
  • Angioimmunoblastic T Cell Lymphoma
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • Recurrent Adult T-cell Leukemia/Lymphoma
  • Recurrent Mycosis Fungoides/Sezary Syndrome
  • Hepatosplenic T Cell Lymphoma
  • Peripheral T Cell Lymphoma
  • Small Intestine Lymphoma
  • Splenic Marginal Zone Lymphoma
  • Post Transplant Lymphoproliferative Disorder
  • Recurrent Adult Burkitt Lymphoma
  • Waldenstrom Macroglobulinemia
  • Recurrent Adult Diffuse Large Cell Lymphoma
  • Recurrent Adult Lymphoblastic Lymphoma
  • Recurrent Grade 3 Follicular Lymphoma
Type
Interventional
Phase
Phase 2
Design
Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

PRIMARY OBJECTIVES: I. To evaluate the proportion of confirmed response of LBH589 in patients with relapsed or refractory non-Hodgkin lymphoma. SECONDARY OBJECTIVES: I. To describe the toxicities associated with LBH589 in patients with NHL. II. To evaluate overall survival, progression-free survival...

PRIMARY OBJECTIVES: I. To evaluate the proportion of confirmed response of LBH589 in patients with relapsed or refractory non-Hodgkin lymphoma. SECONDARY OBJECTIVES: I. To describe the toxicities associated with LBH589 in patients with NHL. II. To evaluate overall survival, progression-free survival, and duration of response in patients treated with LBH589. TERTIARY OBJECTIVES: I. To evaluate the pharmacokinetics of LBH589. II. To assess the correlation between clinical (toxicity and/or tumor response or activity) effects with the pharmacologic (pharmacokinetic/pharmacodynamic) parameters, and/or biologic (correlative laboratory) results. OUTLINE: Patients receive oral panobinostat 3 times weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 6 months for up to 2 years.

Tracking Information

NCT #
NCT01261247
Collaborators
National Cancer Institute (NCI)
Investigators
Study Chair: Patrick Johnston, M.D. Mayo Clinic